Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2011 06:20 ET | Source: ImmunoGen, Inc.

ImmunoGen, Inc. Earns Milestone With Start of SAR3419 Phase II Testing

WALTHAM, Mass., Oct. 20, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody...
October 13, 2011 06:01 ET | Source: ImmunoGen, Inc.

ImmunoGen, Inc. Announces Webcast of Presentation at the 18th Annual NewsMakers in the Biotech Industry Conference

WALTHAM, Mass., Oct. 13, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its...
September 24, 2011 18:02 ET | Source: ImmunoGen, Inc.

T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer

Notable results from Genentech/Roche Phase II trial are featured in conference's official press program T-DM1 utilizes ImmunoGen's Targeted Antibody Payload (TAP) technology with the...
September 22, 2011 16:01 ET | Source: ImmunoGen, Inc.

ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma

WALTHAM, Mass., Sept. 22, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody...
August 31, 2011 06:31 ET | Source: ImmunoGen, Inc.

ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences

WALTHAM, Mass., Aug. 31, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and...